Introduction {#tca12987-sec-0005}
============

Lung cancer has been the most common cancer worldwide for decades.[1](#tca12987-bib-0001){ref-type="ref"}, [2](#tca12987-bib-0002){ref-type="ref"} Investigations conducted among different populations have found significant differences in the epidemiological, clinical, and molecular characteristics of lung cancer patients, especially non‐smokers, and that natural genetic susceptibility and fossil fuel use are important factors in the etiology of lung cancer.[2](#tca12987-bib-0002){ref-type="ref"}, [3](#tca12987-bib-0003){ref-type="ref"}, [4](#tca12987-bib-0004){ref-type="ref"}, [5](#tca12987-bib-0005){ref-type="ref"}, [6](#tca12987-bib-0006){ref-type="ref"}, [7](#tca12987-bib-0007){ref-type="ref"} An epidemiological survey proved that lung cancer has familial aggregation, after adjusting for tobacco smoking and other environmental factors.[8](#tca12987-bib-0008){ref-type="ref"}, [9](#tca12987-bib-0009){ref-type="ref"}, [10](#tca12987-bib-0010){ref-type="ref"}, [11](#tca12987-bib-0011){ref-type="ref"} Most studies have found an increased risk associated with a family history of lung cancer (FLC), which varies 1.3--3.5‐fold.[8](#tca12987-bib-0008){ref-type="ref"}, [9](#tca12987-bib-0009){ref-type="ref"}, [10](#tca12987-bib-0010){ref-type="ref"}, [11](#tca12987-bib-0011){ref-type="ref"}, [12](#tca12987-bib-0012){ref-type="ref"}, [13](#tca12987-bib-0013){ref-type="ref"}, [14](#tca12987-bib-0014){ref-type="ref"} Unlike other typical familial cancers, such as breast and colorectal cancer, genetic susceptibility to lung cancer has not been studied. Lung cancer has a range of well‐known risk factors, such as smoking, mining, shipbuilding, industrial construction, and the occupational hazards of petroleum refining.[11](#tca12987-bib-0011){ref-type="ref"} Globally, approximately 53% of lung cancer cases in women and 15% in men are not related to smoking.[5](#tca12987-bib-0005){ref-type="ref"} Statistics suggest that approximately 3 billion people on earth use coal or biomass for cooking and heating purposes.[15](#tca12987-bib-0015){ref-type="ref"}, [16](#tca12987-bib-0016){ref-type="ref"} This practice poses a long‐term risk of the development of cardiovascular and respiratory diseases, including lung cancer.[3](#tca12987-bib-0003){ref-type="ref"}, [15](#tca12987-bib-0015){ref-type="ref"}, [16](#tca12987-bib-0016){ref-type="ref"}, [17](#tca12987-bib-0017){ref-type="ref"} Evidence suggests that lung cancer caused by other non‐tobacco factors has unique clinical and histological characteristics compared to lung cancer caused by smoking.[4](#tca12987-bib-0004){ref-type="ref"}, [5](#tca12987-bib-0005){ref-type="ref"}, [6](#tca12987-bib-0006){ref-type="ref"}, [7](#tca12987-bib-0007){ref-type="ref"}

Notably, Xuanwei, Yunnan Province, China, has long been the focus of large‐scale epidemiological studies, reporting some of the highest rates of lung cancer in the world, especially among people who have never smoked.[7](#tca12987-bib-0007){ref-type="ref"}, [17](#tca12987-bib-0017){ref-type="ref"}, [18](#tca12987-bib-0018){ref-type="ref"} This has partially been attributed to coal combustion.[3](#tca12987-bib-0003){ref-type="ref"}, [16](#tca12987-bib-0016){ref-type="ref"} The incidence of lung cancer in these rural areas also shows characteristics of family aggregation.[17](#tca12987-bib-0017){ref-type="ref"} The shared environment can partly explain this phenomenon, but the influence of a genetic background of susceptibility cannot be ignored.

Patients from this region could represent a good model to study the intricate mechanisms of lung cancer etiology. Although much work has been done, the dynamic and complex interactions between environmental carcinogens and human genetic background remain a mystery.[4](#tca12987-bib-0004){ref-type="ref"}, [19](#tca12987-bib-0019){ref-type="ref"} Research has suggested that non‐smokers and patients exposed to coal combustion exhibit unique driver mutation patterns and fusion genes, such as *ALK* and *ROS1*, which exhibit special signatures in NSCLC.[4](#tca12987-bib-0004){ref-type="ref"}, [6](#tca12987-bib-0006){ref-type="ref"}, [7](#tca12987-bib-0007){ref-type="ref"}, [19](#tca12987-bib-0019){ref-type="ref"} To better characterize the interaction between these two key players, this study investigated the clinical characteristics and genetic rearrangements of people with FLC and a history of exposure to coal combustion, one representing genetic causes and the other key environmental factors. Compared to fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC), reverse transcription (RT)‐PCR can detect fusion genes, including variant types. It is also a fast, sensitive, high‐flux method.[20](#tca12987-bib-0020){ref-type="ref"}, [21](#tca12987-bib-0021){ref-type="ref"}, [22](#tca12987-bib-0022){ref-type="ref"}

Methods {#tca12987-sec-0006}
=======

Patients and tissue samples {#tca12987-sec-0007}
---------------------------

Patients with pathologically confirmed lung cancer in Ward One at the Department of Thoracic Surgery, Yunnan Cancer Hospital between February 2014 and June 2017 were included. To study the effect of FLC and exposure to occupational or household coal combustion, we focused on patients with both characteristics, based on the following criteria: (i) FLC was defined as individuals with three or more first‐degree relatives affected by lung cancer (*n* = 192); and (ii) patients without FLC were enrolled as a control, defined as individuals with no reported cancer diagnosed among first‐degree relatives for three generations. Eventually, 218 patients met the criteria. Patients' exposure to occupational or domestic coal combustion was also documented. Patients with occupational coal combustion exposure, mainly residents from Xuanwei and other rural areas, include farmers who use coal to heat agricultural facilities and workers, such as furnacemen, exposed to carcinogens related to burning coal. Residents use coal domestically to cook and heat their homes. Smoking history and occupational or domestic coal exposure was obtained based on self‐report and confirmed by personal medical records.

Clinical and pathologic data were obtained from the hospital cooperated databank (<https://www.linkdoc.com>), which included age, gender, histologic type, family history, smoking status, occupational exposure, and critical environmental risk factors. Tumor node metastasis (TNM) stage was reviewed according to the 8th edition of the International Association for the Study of Lung Cancer (IASLC) staging system. The majority of patients enrolled had adenocarcinoma (AD) and squamous cell carcinoma (SCC); other histology types were not included as few patients met the inclusion criteria.

Lung cancer tissues were stored in RNAlater (Sigma, St. Louis, MO, USA) immediately after surgery. A slide was cut from each sample for hematoxylin and eosin staining. Those containing \> 70% cancer cells and \< 10% necrosis were enrolled. The ethical committees of Yunnan Cancer Hospital approved the study. All patients signed informed consent.

RNA extraction and reverse transcription‐PCR {#tca12987-sec-0008}
--------------------------------------------

Total RNA was extracted using a TRIzol Reagent Kit (Invitrogen, Carlsbad, CA, USA), and then incubated with RNase‐free DNase I (Qiagen, Hilden, Germany) to remove contaminating DNA. RT was performed using a reverse transcription kit (Promega, Madison, WI, USA) to generate complementary DNA as PCR templates. RT‐PCR was performed using Sigma Taq (Sigma).

PCR products were first detected by electrophoresis and those with proper bands were sequenced by BGI Tech (Shenzhen, China; <http://www.bgitechsolutions.com>) for confirmation. The nucleotide sequences were verified using the BLAST program (National Center for Biotechnology Information, Bethesda, MD, USA). All positive cases were confirmed by another independent PCR reaction.

*ALK* rearrangement {#tca12987-sec-0009}
-------------------

Primers were selected based on reference to identify different *EML4‐ALK* variants (Table [S1](#tca12987-supitem-0001){ref-type="supplementary-material"}).[22](#tca12987-bib-0022){ref-type="ref"}, [23](#tca12987-bib-0023){ref-type="ref"}, [24](#tca12987-bib-0024){ref-type="ref"}, [25](#tca12987-bib-0025){ref-type="ref"} The thermal cycle conditions were as follows: *EML4‐ALK* variant 1: 95°C, 5 minutes, 40 cycles of 95°C, 30 seconds, 55°C, 30 seconds, 72°C, 1 minute; and *EML4‐ALK* variants 2--7: 95°C, 10 minutes, 40 cycles of 95°C, 30 seconds, 66°C, 30 seconds, 72°C, 2.5 minutes.

Other *ALK* rearrangements were also examined in the negative samples for *EML4‐ALK*, including *TFG‐ALK*, *KLC1‐ALK*, and *KIF5B‐ALK.* The primers and PCR conditions were designed based on previous reports (Table [S1](#tca12987-supitem-0001){ref-type="supplementary-material"}):[26](#tca12987-bib-0026){ref-type="ref"}, [27](#tca12987-bib-0027){ref-type="ref"}, [28](#tca12987-bib-0028){ref-type="ref"} *KIF5B‐ALK*: 95°C, 5 minutes, 40 cycles of 95°C, 30 seconds, 50°C, 30 seconds, 72°C, 2.5 minutes; *KLC1‐ALK*: 95°C, 5 minutes, 40 cycles of 95°C, 40 seconds, 55°C, 40 seconds, 72°C, 3 minutes; and *TFG‐ALK*: 95°C, 5 minutes, 40 cycles of 94°C, 40 seconds, 65°C, 40 seconds, 72°C, 1.5 minutes.

*ROS1* rearrangement {#tca12987-sec-0010}
--------------------

Different *ROS1* fusions were examined, including *CD74‐ROS1*, *TPM3‐ROS1*, *EZR‐ROS1*, *SLC34A2‐ROS1*, *LRIG3‐ROS1*, *GOPC‐ROS1*, and *SDC4‐ROS1.* The primers and PCR conditions were designed based on previous studies (Table [S1](#tca12987-supitem-0001){ref-type="supplementary-material"}).[29](#tca12987-bib-0029){ref-type="ref"}, [30](#tca12987-bib-0030){ref-type="ref"} The PCR conditions were as follows: 95°C, 5 minutes, 10 cycles of touchdown PCR (annealing from 63 to 58°C with a 0.5 decrease each cycle) and 30 cycles of 95°C, 40 seconds, 58°C, 40 seconds, 72°C, 1 minute, with a final extension of 72°C for 5 minutes.

*RET* rearrangement {#tca12987-sec-0011}
-------------------

The potential existence of *CCDC6‐RET* and *KIF5B‐RET* were also examined. The primers and PCR conditions were set according to a previous study (Table [S1](#tca12987-supitem-0001){ref-type="supplementary-material"}).[31](#tca12987-bib-0031){ref-type="ref"} The program for *CCDC6‐RET* was: 95°C, 4 minutes, 40 cycles of 95°C, 30 seconds, 60°C, 30 seconds, 72°C, 30 seconds. The program for *KIF5B‐RET* was: 95°C, 4 minutes, 40 cycles of 95°C, 30 seconds, 62°C, 30 seconds, 72°C, 30 seconds.

*NTRK1* rearrangement {#tca12987-sec-0012}
---------------------

The rarely reported *CD74‐NTRK1* fusion was also examined. The primers and PCR conditions were set based on a previous report (Table [S1](#tca12987-supitem-0001){ref-type="supplementary-material"}).[32](#tca12987-bib-0032){ref-type="ref"} The PCR conditions were as follows: 95°C, 4 minutes, 10 cycles of touchdown PCR (annealing from 62 to 57°C with a 0.5 decrease each cycle) and 30 cycles of 95°C, 40 seconds, 57°C, 40 seconds, 72°C, 1 minute.

Statistical analysis {#tca12987-sec-0013}
--------------------

Chi‐square and Fischer\'s exact tests were used to analyze the association of clinicopathological parameters with FLC and occupational/domestic coal exposure. SPSS version 17.0 (SPSS, Chicago, IL, USA) was used. Statistical significance was set at *P* \< 0.05 (two‐sided *P* value).

Results {#tca12987-sec-0014}
=======

Clinicopathological features of the study population {#tca12987-sec-0015}
----------------------------------------------------

In total, 410 lung cancer patients were included. The clinicopathological characteristics are shown in Tables [1](#tca12987-tbl-0001){ref-type="table"} and [2](#tca12987-tbl-0002){ref-type="table"}. There were 277 men and 133 women at an average age of 59 (range 28--84) years; 192 patients (male: 114, female: 78) had FLC while 218 (male: 163, female: 55) reported no FLC. The histological subtypes included 326 (79.5%) AD and 84 (20.5%) SCC. A total of 204 (49.8%; male: 177, female: 27) patients were exposed to occupational or domestic coal combustion and 231 (56.3%, all male) were smokers, among whom 173 (42.2%) were both smokers and exposed to coal combustion. To better evaluate major carcinogen exposure in the sample population, both factors were considered together. The definition of high exposure was either being a smoker or exposed to coal combustion, while low exposure was defined as a non‐smoker not exposed to coal combustion. A total of 262 (63.9%, male: 235, female: 27) subjects were classified in the high carcinogen exposure group.

###### 

Clinical characteristics of 410 NSCLC patients grouped by FLC and exposure level

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                               Total\                    High exposure group\               Low exposure group\                                   
                                               FLC\                      FLC\                               FLC\                                                  
                                               Case (%)                  Case (%)                           Case (%)                                              
  -------------------------------------- ----- ------------ ------------ ---------------------- ----------- --------------------- ------- ----------- ----------- -------
  Total number of patients               410   192 (46.8)   218 (53.2)                          94 (24.4)   168 (64.1)                    98 (66.2)   50 (33.8)   

  Gender                                                                 0.001                                                       0                            0

  Male                                   277   114 (59.4)   163 (74.8)                          75 (79.8)   160 (95.2)                    39 (39.8)   3 (6.0)     

  Female                                 133   78 (40.6)    55 (25.2)                           19 (20.2)   8 (4.8)                       59 (60.2)   47 (94.0)   

  Average age: 59 years (range 28--84)                                   0                                                           0                            0.037

  ≤ 55 years                             145   104 (54.2)   41 (18.8)                           55 (58.5)   25 (14.9)                     49 (50.0)   16 (32.0)   

  \> 55 years                            265   88 (45.8)    177 (81.2)                          39 (41.5)   143 (85.1)                    49 (50.0)   34 (68.0)   

  Histological type                                                      0                                                           0                            0.550

  Adenocarcinoma                         326   180 (93.7)   146 (67.0)                          84 (89.4)   96 (57.1)                     96 (98.0)   50 (100)    

  Squamous cell carcinoma                84    12 (6.3)     72 (33.0)                           10 (10.6)   72 (42.9)                     2 (2.0)     0 (0)       

  T                                                                      0.138                                                     0.54                           0.25

  T1                                     69    34 (17.7)    35 (16.1)                           14 (14.9)   24 (14.3)                     20 (20.4)   11 (22.0)   

  T2                                     178   75 (39.1)    103 (47.2)                          36 (38.3)   77 (45.8)                     39 (39.8)   26 (52.0)   

  T3                                     65    28 (14.6)    37 (17.0)                           17 (18.1)   31 (18.5)                     11 (11.2)   6 (12.0)    

  T4                                     98    55 (28.6)    43 (19.7)                           27 (28.7)   36 (21.4)                     28 (28.6)   7 (14.0)    

  N                                                                      0.033                                                     0.21                           0.18

  N0                                     153   70 (36.5)    83 (38.1)                           29 (30.9)   63 (37.5)                     41 (41.8)   20 (40.0)   

  N1                                     33    10 (5.2)     23 (10.6)                           6 (6.4)     18 (10.7)                     4 (4.1)     5 (10.0)    

  N2                                     129   57 (29.7)    72 (33.0)                           32 (34.0)   55 (32.7)                     25 (25.5)   17 (34.0)   

  N3                                     95    55 (28.6)    40 (18.3)                           27 (28.7)   32 (19.0)                     28 (28.6)   8 (16.0)    

  M                                                                      0                                                         0.007                          0.004

  M0                                     255   99 (54.4)    156 (71.6)                          51 (54.3)   119 (70.8)                    48 (49.0)   37 (74.0)   

  M1                                     155   93 (45.6)    62 (28.4)                           43 (45.7)   49 (29.2)                     50 (51.0)   13 (26.0)   

  Stage                                                                  0                                                         0.037                          0

  I                                      98    45 (23.4)    53 (24.3)                           16 (17.0)   42 (25.0)                     29 (29.6)   11 (22.0)   

  II                                     51    17 (8.8)     34 (15.6)                           8 (8.5)     25 (14.9)                     9 (9.2)     9 (18.0)    

  III                                    106   37 (19.3)    69 (31.7)                           27 (28.7)   52 (31.0)                     10 (10.2)   17 (34.0)   

  IV                                     155   93 (48.4)    62 (28.4)                           43 (45.7)   49 (29.2)                     50 (51.0)   13 (26.0)   
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------

*P* value calculated by chi‐square or Fisher\'s exact test, when there is at least one cell with an expected count \< 5.

High exposure is defined as being a smoker or exposed to coal use, while low exposure refers non‐smokers and no coal exposure. FLC, family history of lung cancer; NSCLC, non‐small cell lung cancer.

###### 

Clinical characteristics of gene rearrangements detected by reverse transcription‐PCR in 410 NSCLC patients

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                    *ALK* rearrangements\                 *ROS1* rearrangements\             Total rearrangements\                                    
                                                    Case (%)                                     Case (%)                    Case (%)                                                 
  ------------------------------------------- ----- ----------------------- ------------ ------------------------ ---------- ----------------------- ------- ----------- ------------ -------
  Total number of patients                    410   51 (12.4)               359 (87.6)                            16 (3.9)   394 (96.1)                      67 (16.3)   343 (83.7)   

  Gender                                                                                            0                                                   0                                0

  Male                                        277   22 (7.9)                255 (92.1)                            3 (1.1)    274 (98.9)                      25 (9.0)    252 (91.0)   

  Female                                      133   29 (21.8)               104 (78.2)                            13 (9.8)   120 (90.2)                      42 (31.6)   91 (68.4)    

  Average age: 59 years (range 28--84)                                                            0.002                                               0.001                              0

  ≤55 years                                   145   28 (19.3)               117 (80.7)                            12 (8.3)   133 (91.7)                      40 (27.6)   105 (72.4)   

  \> 55 years                                 265   23 (8.7)                242 (91.3)                            4 (1.5)    261 (98.5)                      27 (10.2)   238 (89.8)   

  Histological type                                                                               0.006                                               0.05                               0

  Adenocarcinoma                              326   48 (14.7)               278 (85.3)                            16 (4.9)   310 (95.1)                      64 (19.6)   262 (80.4)   

  Squamous cell carcinoma                     84    3 (3.6)                 81 (96.4)                             0 (0)      84 (100)                        3 (3.6)     81 (96.4)    

  Stage                                                                                           0.013                                               0.87                             0.014

  I                                           98    15 (15.3)               83 (84.7)                             5 (5.1)    93 (94.9)                       20 (25.6)   78 (74.4)    

  II                                          51    6 (11.8)                45 (88.2)                             2 (3.9)    49 (96.1)                       8 (15.7)    43 (84.3)    

  III                                         106   4 (3.8)                 102 (96.2)                            3 (2.8)    103 (97.2)                      7 (6.6)     99 (93.4)    

  IV                                          155   26 (16.8)               129 (83.2)                            6 (3.9)    149 (96.1)                      32 (20.6)   123 (79.4)   

  Smoking history                                                                                   0                                                 0.002                              0

  Yes (Current or ex‐smoker)                  231   17 (7.4)                214 (92.6)                            3 (1.3)    228 (98.7)                      20 (8.7)    211 (91.3)   

  Never                                       179   34 (19.0)               145 (81.0)                            13 (7.3)   166 (92.7)                      47 (26.3)   132 (73.7)   

  Occupational or domestic coal use                                                               0.022                                               0.98                             0.041

  Yes (current or ex‐user)                    204   33 (16.2)               171 (83.8)                            8 (3.9)    196 (96.1)                      41 (20.1)   163 (79.9)   

  Never                                       206   18 (8.7)                188 (91.3)                            8 (3.9)    198 (96.1)                      26 (12.6)   180 (87.4)   

  Overall exposure level (tobacco and coal)                                                       0.046                                               0.68                             0.046

  High (smoker or household coal‐user)        262   39 (14.9)               223 (85.1)                            11 (4.2)   251 (95.8)                      50 (19.1)   212 (80.9)   

  Low (never smoker & never coal‐user)        148   12 (8.1)                136 (91.9)                            5 (3.4)    143 (96.6)                      17 (11.5)   131 (88.5)   

  Family history of lung cancer                                                                   0.001                                               0.07                               0

  Present                                     192   35 (18.2)               157 (81.8)                            11 (5.7)   181 (94.3)                      46 (24.0)   146 (76.0)   

  Absent                                      218   16 (7.3)                202 (92.7)                            5 (2.3)    213 (97.7)                      21 (9.6)    197 (90.4)   

  Family history in high exposure group                                                             0                                                 0.06                               0

  Present                                     94    26 (27.7)               68 (72.3)                             7 (7.4)    87 (92.6)                       33 (35.1)   61 (64.9)    

  Absent                                      168   13 (7.7)                155 (92.3)                            4 (2.4)    164 (97.6)                      17 (10.1)   151 (89.9)   

  Family history in low exposure group                                                             0.75                                               0.66                             0.34

  Present                                     98    9 (9.2)                 89 (90.8)                             4 (4.1)    94 (95.9)                       13 (13.3)   85 (86.7)    

  Absent                                      50    3 (6.0)                 47 (94.0)                             1 (2.0)    49 (98.0)                       4 (8.0)     46 (92.0)    
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*P* value calculated by chi‐square or Fisher\'s exact test, when there is at least one cell with an expected count \< 5.

NSCLC, non‐small cell lung cancer.

Patients with a family history of lung cancer (FLC): Younger and with a higher female ratio {#tca12987-sec-0016}
-------------------------------------------------------------------------------------------

Significantly more women had FLC (*P* \< 0.01). Because men dominated the smoking population, most women were never smokers. There were more men in the high exposure than in the low exposure group (Table [1](#tca12987-tbl-0001){ref-type="table"}, Fig [1](#tca12987-fig-0001){ref-type="fig"}a). Importantly, the distribution of patient age also reveals interesting variation in different subpopulations. The age structure curve of FLC patients increased compared to patients without FLC: there were significantly more individuals aged \< 55 (*P* \< 0.01) (Table [1](#tca12987-tbl-0001){ref-type="table"}, Fig [1](#tca12987-fig-0001){ref-type="fig"}b). A similar apparent age difference was observed in subgroups (Fig [1](#tca12987-fig-0001){ref-type="fig"}c). Men with FLC developed the disease much earlier than those without (median age: 55 vs. 64 years), while in women the age gap was smaller (median age: with FLC 53.5 vs. without FLC 57 years). On the other hand, if first divided by overall exposure (tobacco and coal), subjects in the same exposure group were still affected by FLC: FLC patients were younger than their counterparts. The age gap was much larger in the high exposure (median age: with FLC 53 vs. without FLC 63 years) compared to the low exposure group (median age: with FLC 55.5 vs. without FLC 58.5 years).

![Patient age, gender, histology, and stage distribution. (**a**) Gender ratio in different subgroups. (![](TCA-10-695-g004.jpg "image")) Female, and (![](TCA-10-695-g005.jpg "image")) Male. (**b**) Patient age structure curves. Both fitted curves were 5th‐degree polynomial; the function for FLC patients is: y = −4E−07x^5^ + 0.0001x^4^−0.015x^3^ + 0.8543x^2^−23x + 234.51 (R^2^ = 0.715); and for patients without FLC is: y = 8E−07x^5^−0.0002x^4^ + 0.0228x^3^−1.1361x^2^ + 27.063x−247.71 (R^2^ = 0.8616) (![](TCA-10-695-g006.jpg "image")) Positive, and (![](TCA-10-695-g007.jpg "image")) Negative. (**c**) Patient age distribution in subgroups. Patient histology and tumor node metastasis stage divided by (**d--h**) exposure level (![](TCA-10-695-g008.jpg "image")) AD, and (![](TCA-10-695-g009.jpg "image")) SCC; (![](TCA-10-695-g010.jpg "image")) Stage I, (![](TCA-10-695-g011.jpg "image")) Stage II, (![](TCA-10-695-g012.jpg "image")) Stage III, and (![](TCA-10-695-g013.jpg "image")) Stage IV; (![](TCA-10-695-g014.jpg "image")) T1, (![](TCA-10-695-g015.jpg "image")) T2, (![](TCA-10-695-g016.jpg "image")) T3, and (![](TCA-10-695-g017.jpg "image")) T4; (![](TCA-10-695-g018.jpg "image")) N0, (![](TCA-10-695-g019.jpg "image")) N1, (![](TCA-10-695-g020.jpg "image")) N2, and (![](TCA-10-695-g021.jpg "image")) N3; (![](TCA-10-695-g022.jpg "image")) M0, and (![](TCA-10-695-g023.jpg "image")) M1 and (**i--m**) gender (![](TCA-10-695-g024.jpg "image")) AD, and (![](TCA-10-695-g025.jpg "image")) SCC; (![](TCA-10-695-g026.jpg "image")) Stage I, (![](TCA-10-695-g027.jpg "image")) Stage II, (![](TCA-10-695-g028.jpg "image")) Stage III, and (![](TCA-10-695-g029.jpg "image")) Stage IV; (![](TCA-10-695-g030.jpg "image")) T1, (![](TCA-10-695-g031.jpg "image")) T2, (![](TCA-10-695-g032.jpg "image")) T3, and (![](TCA-10-695-g033.jpg "image")) T4; (![](TCA-10-695-g034.jpg "image")) N0, (![](TCA-10-695-g035.jpg "image")) N1, (![](TCA-10-695-g036.jpg "image")) N2, and (![](TCA-10-695-g037.jpg "image")) N3; (![](TCA-10-695-g038.jpg "image")) M0, and (![](TCA-10-695-g039.jpg "image")) M1](TCA-10-695-g001){#tca12987-fig-0001}

FLC patients: Dominated by adenocarcinoma and a higher frequency of later stage diagnosis {#tca12987-sec-0017}
-----------------------------------------------------------------------------------------

Clinical characteristics were first divided according to gender and total exposure level, and then the effects of FLC were further compared between total and subgroup exposure level. AD was the major histological type in all subgroups (Table [1](#tca12987-tbl-0001){ref-type="table"}), but there were statistically more cases of SCC in subgroups negative for FLC, whether divided by gender or exposure (Fig 1d,i). There was a higher percentage of stage IV patients in the FLC subgroup (*P* \< 0.05) within the same gender or exposure group (Fig 1e,j). FLC patients had more T4 and N3 disease, but only the N stage in total was statistically significant (Fig 1f,g,k,l). The greatest variation was in M stage, where FLC patients in all groups experienced significantly more distant metastasis (*P* \< 0.05) (Fig 1h,m). Overall, patients with FLC had a higher risk of lymph node and other organ metastasis. The influence of FLC was consistent in the same gender or within the same exposure group.

*ALK* rearrangement: Associated with younger age, women, and never smokers {#tca12987-sec-0018}
--------------------------------------------------------------------------

Of the total 410 patients, 51 (12.4%: 22 men 7.9%, 29 women 21.8%) had *ALK* rearrangement (Table [2](#tca12987-tbl-0002){ref-type="table"}). Patients with *ALK* fusion were younger (*P* \< 0.01), with 28 (28/145, 19.3%) aged \< 55 and 23 (23/265, 8.7%) aged \> 55. The pathological diagnoses included 48 cases with AD and three cases with SCC (*P* \< 0.01). The positive cases mainly occurred in stages I (15/51, 29.4%) and IV (26/51, 51.0%). Importantly, 4/15 (26.7%) patients in stage I were FLC positive, while 24/26 (92.3%) in stage IV were FLC positive. *ALK* rearrangement was significantly associated with female gender (*P* \< 0.01) and non‐smoking status (*P* \< 0.01). All 51 patients had *EML4‐ALK* fusion: 17 were variant 1, 6 were variant 2, and 28 were variant 3a/3b (Table [S2](#tca12987-supitem-0001){ref-type="supplementary-material"}).

*ALK* rearrangement: Associated with FLC and coal exposure {#tca12987-sec-0019}
----------------------------------------------------------

In this series, *ALK* rearrangement was strongly associated with FLC (*P* \< 0.01): 35 patients (35/192, 18.2%) were positive (Table [2](#tca12987-tbl-0002){ref-type="table"}). Because genetic and environmental factors both contribute to gene mutation, subjects were further compared within the same exposure group. In the high exposure group, a high association existed between *ALK* fusion and FLC (*P* \< 0.01). However, no significant association was found between *ALK* fusion and FLC in the low exposure group. In addition, *ALK* rearrangement was significantly associated with occupational or domestic coal combustion (*P* \< 0.05): 33 patients (33/204, 16.2%) were current or ex‐coal users, while 18 (18/206, 8.7%) had never been exposed to coal combustion. When smoking and coal use were combined as overall exposure (tobacco and coal), the association still existed (*P* \< 0.05): 39 (39/262, 14.9%) were either a coal user or a smoker, and 12 (12/148, 8.1%) were never‐coal users and never‐smokers.

*ROS1* rearrangement: Associated with younger age, women, and non‐smokers {#tca12987-sec-0020}
-------------------------------------------------------------------------

Among the 410 patients, 16 (3.9%: 3 men, 3/277, 1.1%; 13 women, 13/133, 9.8%) harbored *ROS1* rearrangements (Table [2](#tca12987-tbl-0002){ref-type="table"}). A statistically significant association was found for female gender and non‐smoking. Most subjects with *ROS1* fusion were also younger (*P* \< 0.01): 12 (12/145, 8.3%) were aged \< 55 years and only 4 (4/265, 1.5%) were aged \> 55. All 16 cases were diagnosed as adenocarcinoma: 10 patients had *CD74‐ROS1* (E6/E34) fusion and the other six had unknown type (Table [S3](#tca12987-supitem-0001){ref-type="supplementary-material"}); none had a co‐existing *ALK* rearrangement. Other *ROS1* fusions were not identified. No statistically significant association was observed for stage, histology type, or exposure to occupational or domestic coal combustion. The association between *ROS1* translocation and FLC was also not significant (*P* = 0.07): 11 (11/16, 68.8%) *ROS1* fusion cases had FLC (Fig [2](#tca12987-fig-0002){ref-type="fig"}a,b).

![Total gene fusion distribution based on family history of lung cancer (FLC) and overall exposure level. FLC positive and (**a**) high and (**b**) low exposure. FLC negative and (**c**) high and (**d**) low exposure. (![](TCA-10-695-g040.jpg "image")) *ALK* male, (![](TCA-10-695-g041.jpg "image") *) ALK* female, (![](TCA-10-695-g042.jpg "image")) *ROS1* male, and (![](TCA-10-695-g043.jpg "image")) *ROS1* female](TCA-10-695-g002){#tca12987-fig-0002}

Other gene rearrangements {#tca12987-sec-0021}
-------------------------

Although potential *RET* and *NTRK1* rearrangement were analyzed in all samples, no positive case was identified. This may have been a result of sample size and selection standards. Detection of other gene rearrangements can be performed in a larger sample or in populations of a different composition.

Total gene fusion pattern: Associated with women, never smokers, younger age, FLC, and coal exposure {#tca12987-sec-0022}
----------------------------------------------------------------------------------------------------

All detected gene rearrangements were combined for evaluation (Table [2](#tca12987-tbl-0002){ref-type="table"}). A total of 67 cases (67/410, 16.3%) were identified, including 64 AD and 3 SCC (*P* \< 0.01). Most fusion cases occurred in stages I and IV (Fig [2](#tca12987-fig-0002){ref-type="fig"}). A statistically significant association was also found for female gender and never smokers (*P* \< 0.01). The majority of gene fusions (40/67, 59.7%) occurred in patients aged \< 55 years (*P* \< 0.01). When evaluated by coal exposure status and overall exposure (tobacco and coal), the association was significant (*P* \< 0.05). A total gene fusion event was statistically associated with FLC (*P* \< 0.01): 46 patients (46/67, 68.7%) were positive for FLC, and the association was stronger in the high exposure (*P* \< 0.01) than in the low exposure group (*P* \< 0.05).

*ALK* fusion: Asian studies revealed cross‐population/subpopulation similarities and heterogeneity {#tca12987-sec-0023}
--------------------------------------------------------------------------------------------------

Asian studies on lung cancer patients that provided details of ethnicity, gender, and smoking status with *ALK* fusion are summarized in Table [S4](#tca12987-supitem-0001){ref-type="supplementary-material"}.[2](#tca12987-bib-0002){ref-type="ref"}, [20](#tca12987-bib-0020){ref-type="ref"}, [21](#tca12987-bib-0021){ref-type="ref"}, [22](#tca12987-bib-0022){ref-type="ref"}, [23](#tca12987-bib-0023){ref-type="ref"}, [25](#tca12987-bib-0025){ref-type="ref"}, [27](#tca12987-bib-0027){ref-type="ref"}, [31](#tca12987-bib-0031){ref-type="ref"}, [33](#tca12987-bib-0033){ref-type="ref"}, [34](#tca12987-bib-0034){ref-type="ref"}, [35](#tca12987-bib-0035){ref-type="ref"}, [36](#tca12987-bib-0036){ref-type="ref"}, [37](#tca12987-bib-0037){ref-type="ref"}, [38](#tca12987-bib-0038){ref-type="ref"}, [39](#tca12987-bib-0039){ref-type="ref"}, [40](#tca12987-bib-0040){ref-type="ref"}, [41](#tca12987-bib-0041){ref-type="ref"}, [42](#tca12987-bib-0042){ref-type="ref"}, [43](#tca12987-bib-0043){ref-type="ref"}, [44](#tca12987-bib-0044){ref-type="ref"}, [45](#tca12987-bib-0045){ref-type="ref"}, [46](#tca12987-bib-0046){ref-type="ref"}, [47](#tca12987-bib-0047){ref-type="ref"}, [48](#tca12987-bib-0048){ref-type="ref"}, [49](#tca12987-bib-0049){ref-type="ref"}, [50](#tca12987-bib-0050){ref-type="ref"}, [51](#tca12987-bib-0051){ref-type="ref"}, [52](#tca12987-bib-0052){ref-type="ref"}, [53](#tca12987-bib-0053){ref-type="ref"}, [54](#tca12987-bib-0054){ref-type="ref"}, [55](#tca12987-bib-0055){ref-type="ref"}, [56](#tca12987-bib-0056){ref-type="ref"}, [57](#tca12987-bib-0057){ref-type="ref"}, [58](#tca12987-bib-0058){ref-type="ref"} In total, 33 studies were included (China 14, Japan 12, Korea 7). Among 10 837 NSCLC patients, 614 (5.7%) *ALK* rearrangements were identified, with a major positive rate of 1.4--12%. On average, more *ALK* rearrangements occurred in Chinese patients (7.9%), followed by Korean (6.9%) and Japanese (3.2%) (Fig [3](#tca12987-fig-0003){ref-type="fig"}a,b). When considering gender ratio and smoking history, in all three nations *ALK* rearrangement in men occurred 20% less frequently than in women. Interestingly, when *ALK* fusion cases in the 33 studies were combined, never smokers (71.2%) made up the majority carrying *ALK* fusions. When divided by nation, the never smoker ratio harboring *ALK* fusions was 3 in the Chinese group and approximately 2 each in the Japanese and Korean groups (Fig [3](#tca12987-fig-0003){ref-type="fig"}c,d).

![Comparison of 33 Asian studies on *ALK* fusion based on gender and smoking history. (**a**) *ALK* fusions over three nations. Average (**b**) positive rate of *ALK* fusion, (**c**) gender ratio, and (**d**) smoking rate. Relationships between *ALK*+ and (**e**) gender and (**f**) smoking rates. (![](TCA-10-695-g044.jpg "image")) China, (![](TCA-10-695-g045.jpg "image")) Japan, (![](TCA-10-695-g046.jpg "image")) Korea, and (![](TCA-10-695-g047.jpg "image")) Present study. (**g**) Distribution of 33 Asian studies on *ALK* fusion based on gender and smoking rates. (![](TCA-10-695-g048.jpg "image")) China, (![](TCA-10-695-g049.jpg "image")) Japan, and (![](TCA-10-695-g050.jpg "image")) Korea. (**h**) *ALK* fusion of present study (total and subgroups) based on gender and smoking rates. (\**P* \< 0.05) Note: the value of the numerator based on the condition that the denominator is zero was directly used in figures. The black bubble representing the coal exposure subgroup is right behind the transparent purple bubble (high exposure and family history of lung cancer \[FLC\]+). (![](TCA-10-695-g051.jpg "image")) Present study‐Total, (![](TCA-10-695-g052.jpg "image")) FLC+, (![](TCA-10-695-g053.jpg "image")) FLC−, (![](TCA-10-695-g054.jpg "image")) Smoker+, (![](TCA-10-695-g055.jpg "image")) Smoker−, (![](TCA-10-695-g056.jpg "image")) Coal exposure+, (![](TCA-10-695-g057.jpg "image")) Coal exposure−, (![](TCA-10-695-g058.jpg "image")) High exposure group, (![](TCA-10-695-g059.jpg "image")) Low exposure group, (![](TCA-10-695-g060.jpg "image")) High exposure + FLC+, (![](TCA-10-695-g061.jpg "image")) High exposure + FLC−, (![](TCA-10-695-g062.jpg "image")) Low exposure + FLC+, (![](TCA-10-695-g063.jpg "image")) Low exposure + FLC−. High exposure: either being a smoker or exposed to coal combustion; low exposure: not exposed to coal combustion and also a non‐smoker.](TCA-10-695-g003){#tca12987-fig-0003}

Analyses of the relationship between gender, smoking ratio, and *ALK* positive rate yielded quite interesting findings. In all three countries, increases in the number of *ALK* positive patients were associated with increases in the male: female ratio (Fig [3](#tca12987-fig-0003){ref-type="fig"}e). In terms of study distribution, China and Korea were similar, while Japan had less overlapping work with the other two. The trend line was based on 31 studies, excluding one[27](#tca12987-bib-0027){ref-type="ref"} that did not include a gender ratio and one[55](#tca12987-bib-0055){ref-type="ref"} that only included stage IIIB--IV NSCLC patients. On the other hand, in studies with a lower *ALK* positive rate, more never smokers tended to have *ALK* fusion, but the frequency of smokers became higher with increasing *ALK* positive rates; the distribution was similar for all three countries (Fig [3](#tca12987-fig-0003){ref-type="fig"}f). In summary, an increase in the frequency of *ALK* fusion in the subject population was accompanied by rising male ratios in the positive pool. The increase appeared to be related to smoking males, suggesting a potential link between smoking and *ALK* fusion in men.

When gender, smoking history, and *ALK* positive rates were integrated into a plot for evaluation, the majority of studies gathered around the center, but a few drifted away from the main group (Fig [3](#tca12987-fig-0003){ref-type="fig"}g). Most studies fell into the category with a higher frequency of women and never smokers, exhibited a relatively lower positive rate, and focused on stage IIIB--IV NSCLC (with the exception of one study with a much higher positive rate, represented by the large white bubble in Fig 3g, which focused on stage IIIB--IV NSCLC).[55](#tca12987-bib-0055){ref-type="ref"} Studies located in the right upper quadrant included more men and never smokers but showed higher positive rates. Most Chinese, Japanese, and Korean studies focused on the same geographic regions, but a few of the Japanese studies contained little co‐existing work from other ethnic groups, possibly reflecting population variation.

Subgroups by genetic, occupational, or environmental factors could partly recreate heterogeneous distribution of *ALK* fusion from previous reports {#tca12987-sec-0024}
---------------------------------------------------------------------------------------------------------------------------------------------------

Our overall results were consistent with previous work on *ALK* rearrangement, especially those from China (Fig [3](#tca12987-fig-0003){ref-type="fig"}e--g). When our study population was further divided by FLC, smoking status, coal exposure, and overall exposure, the diversity of subgroups gradually took shape.

In total, 12 (6 pairs) subgroups were analyzed: 8 corresponded with the category featuring women and never smokers, similar to the majority of the studies; and 4 with a higher male ratio. Moreover, compared to the 33 Asian studies, 6 subgroups were located near the center, while the other 6 drifted some distance away. Notably, 4 pairs were separated into different quadrants; in only 2 pairs were both subgroups located in the same category (coal user +/−; low exposure, FLC +/−) (Fig [3](#tca12987-fig-0003){ref-type="fig"}h). Interestingly, dividing the population into subgroups featured by genetic, occupational, or environmental factors could at least partly recreate the diversified distribution picture of *ALK* fusion from previous reports.

*ALK* fusion occurred in 18.2% (35/192) of patients with FLC, with a higher ratio of women and non‐smokers, and 7.3% (16/218) in patients without FLC. The *ALK*+ rate in never smokers was 19.0% versus 7.4% in smokers. In *ALK*+ cases, all smokers were men and 85.3% of non‐smokers were women; this subgroup exhibited the greatest difference in results. *ALK*+ occurred more frequently in subjects exposed to coal combustion (16.2% vs. 8.7%) but *ALK*+ cases in both exposed and non‐exposed groups were higher in women and never smokers. In the high exposure group 14.9% (39/262) were *ALK*+ compared to 8.1% (12/148) in the low exposure group; women and never smokers dominated these categories. Patients with both FLC and high exposure exhibited the highest rate of *ALK* rearrangement (26/94, 27.7%) in all subgroups, almost matching the results of a study on advanced NSCLC (30.9%). Interestingly, *ALK* fusion in patients without FLC but high exposure was characterized by more men, smokers, and a moderate positive rate (13/168, 7.7%), contrasting with the results of the majority of the 33 reports included in this analysis;[2](#tca12987-bib-0002){ref-type="ref"}, [20](#tca12987-bib-0020){ref-type="ref"}, [45](#tca12987-bib-0045){ref-type="ref"}, [48](#tca12987-bib-0048){ref-type="ref"}, [54](#tca12987-bib-0054){ref-type="ref"} however, this subgroup was similar as the results of one of the Japanese studies.[46](#tca12987-bib-0046){ref-type="ref"} Finally, regardless of FLC, *ALK*+ patients in the low exposure group were mainly women and non‐smokers, but the positive rate was slightly higher in FLC patients (9.2% vs. 6.0%). Overall, different population compositions contribute to variations in *ALK* rearrangement.

Discussion {#tca12987-sec-0025}
==========

Both genetic and environmental factors contribute to the development of cancer and its mutant spectrum.[2](#tca12987-bib-0002){ref-type="ref"}, [6](#tca12987-bib-0006){ref-type="ref"}, [7](#tca12987-bib-0007){ref-type="ref"}, [13](#tca12987-bib-0013){ref-type="ref"}, [59](#tca12987-bib-0059){ref-type="ref"}, [60](#tca12987-bib-0060){ref-type="ref"} There is abundant evidence of genetic predisposition to lung cancer.[8](#tca12987-bib-0008){ref-type="ref"}, [11](#tca12987-bib-0011){ref-type="ref"}, [13](#tca12987-bib-0013){ref-type="ref"}, [14](#tca12987-bib-0014){ref-type="ref"}, [61](#tca12987-bib-0061){ref-type="ref"} Our study found that regardless of gender and exposure level, FLC patients exhibited some common characteristics: younger age, a high female ratio, AD dominant, increased metastasis, later stage at diagnosis, and higher frequency of gene fusion. Many of these are indicative of increased aggressiveness. Our population had unique characteristics but our results were consistent with previous studies. Findings across previous studies showed both similarity and heterogeneity, depending on the subject source. Some studies reported that certain ethnic groups are affected more by inherited lung cancer susceptibility;[13](#tca12987-bib-0013){ref-type="ref"}, [14](#tca12987-bib-0014){ref-type="ref"} one indicated a lower association between never smokers and FLC;[13](#tca12987-bib-0013){ref-type="ref"} another suggested that FLC is common in never smokers with NSCLC;[9](#tca12987-bib-0009){ref-type="ref"} in regard to gender, some studies found that female relatives have a higher risk compared to male relatives[10](#tca12987-bib-0010){ref-type="ref"}, [61](#tca12987-bib-0061){ref-type="ref"} and similarly, 34% of Spanish women with lung cancer had FLC;[12](#tca12987-bib-0012){ref-type="ref"} and a study that enrolled mainly Caucasian patients found a link between FLC and *EGFR*, rather than *ALK* or *KRAS* mutation.[9](#tca12987-bib-0009){ref-type="ref"} These results indicate that susceptibility to lung cancer may be inherited in a complex pattern across populations, and each population or subpopulation has unique characteristics.

Importantly, FLC tend to have greater impact on lung cancer when subjects were exposed to a high level of carcinogens; studies also report that the lung cancer risk is further amplified by smoking.[14](#tca12987-bib-0014){ref-type="ref"} This was reflected in our results (Fig [1](#tca12987-fig-0001){ref-type="fig"}c): the median age of FLC patients was 10 years younger (53 vs. 63 years) in the high exposure group. On the other hand, if all factors were equal and the study population was divided by pollution level, certain somatic mutation may occur less frequently in an unpolluted environment. Our results showed a smaller age gap in the low exposure group (median age: with FLC 55.5 vs. without FLC 58.5 years). Similarly, regarding *ALK* fusion and total gene rearrangement, the association with FLC was stronger in the high than the low exposure group (Table [2](#tca12987-tbl-0002){ref-type="table"}). Our findings indicate that even within the same exposure group, patients are still affected by FLC, but a susceptible genetic background makes them more vulnerable in a polluted environment.

The *ALK* fusion gene is recognized as an important oncogenic driver gene in NSCLC (main type *EML4‐ALK*).[19](#tca12987-bib-0019){ref-type="ref"}, [24](#tca12987-bib-0024){ref-type="ref"}, [25](#tca12987-bib-0025){ref-type="ref"}, [50](#tca12987-bib-0050){ref-type="ref"} Incidence of *ALK* fusion in NSCLC is approximately 0.99--12%, with no significant differences between Asian and Western populations.[19](#tca12987-bib-0019){ref-type="ref"}, [20](#tca12987-bib-0020){ref-type="ref"}, [49](#tca12987-bib-0049){ref-type="ref"} *ROS1* rearrangement occurs in a small subset (0.5%--2%) of NSCLC patients and is associated with slight or never smokers and adenocarcinoma histology. *CD74‐ROS1* is the major type (\~40%), followed by *EZR‐ROS1* and unknown type (both \~15%).[62](#tca12987-bib-0062){ref-type="ref"} Our results regarding *ALK* and *ROS1* fusion were similar to previous reports with the exception of elevated *ROS1* fusion frequency (3.9%).[29](#tca12987-bib-0029){ref-type="ref"}, [30](#tca12987-bib-0030){ref-type="ref"}, [49](#tca12987-bib-0049){ref-type="ref"}, [62](#tca12987-bib-0062){ref-type="ref"} A meta‐analysis including 1178 *ALK* rearranged cases from 20 541 NSCLC patients indicated that age, gender, smoking status, histology, tumor stage, and ethnicity may be a source of between‐study heterogeneity.[19](#tca12987-bib-0019){ref-type="ref"} According to the reference studies from three nations, there is obvious across population/subpopulation similarity and heterogeneity. Interestingly, similar to the reference reports, our result of an *ALK* fusion increase with a rising male ratio in the positive pool was associated with smoking (Fig [3](#tca12987-fig-0003){ref-type="fig"}e,f), suggesting a potential relationship between smoking and *ALK* fusion in men. However, as many previously published reports from Asian countries found that *ALK* rearrangement is associated with female gender and non‐smokers, this hypothesis requires further investigation.[22](#tca12987-bib-0022){ref-type="ref"}, [36](#tca12987-bib-0036){ref-type="ref"}, [37](#tca12987-bib-0037){ref-type="ref"}, [50](#tca12987-bib-0050){ref-type="ref"}, [54](#tca12987-bib-0054){ref-type="ref"}

One parameter only represents one piece of the puzzle, and for many investigators it can be difficult to collect complete patient data, such as: disease history, personal genetic makeup, and every occupational or environmental risk factor. Therefore, it can be difficult to determine what kinds of missing data may cause differences between study results. Although it is a well‐known assumption that variation between studies is mainly caused by different population compositions,[2](#tca12987-bib-0002){ref-type="ref"}, [19](#tca12987-bib-0019){ref-type="ref"} the division of our study sample into subgroups by genetic, occupational, or environmental factors enabled a picture of diversity in *ALK* fusion to take shape. This not only provided support for the assumption, but also suggested that different kinds of parameters should be carefully considered when conducing cancer research.

When all identified gene rearrangement events were combined for consideration (Fig [2](#tca12987-fig-0002){ref-type="fig"}), inherited susceptibility and exposure to environmental carcinogens appeared to be significant factors causing gene rearrangement. The combination pushed the gene fusion rate to 35.1% (33/94) in the subgroup with both characteristics. The high frequency of gene fusion events and the association with women, never smokers, and younger age may be unique characteristics of the subject population. Other research on lung cancer conducted in this region also found special mutation signatures, such as higher *K‐RAS* mutation rates (15%--29%), compared to other Asian populations (2--7%), including smokers and never smokers.[59](#tca12987-bib-0059){ref-type="ref"}, [63](#tca12987-bib-0063){ref-type="ref"}, [64](#tca12987-bib-0064){ref-type="ref"}, [65](#tca12987-bib-0065){ref-type="ref"} Coal combustion releases a cocktail of carcinogens including polycyclic aromatic hydrocarbons and fine particulate matter (PM~2.5~), many of which are defined by the International Agency for Research on Cancer and the World Health Organization as class I carcinogens.[3](#tca12987-bib-0003){ref-type="ref"}, [16](#tca12987-bib-0016){ref-type="ref"}, [66](#tca12987-bib-0066){ref-type="ref"} Certain carcinogens may have a specific effect on the human genome. For example, *p53* gene mutations in tumors from female never smokers in Xuanwei exhibited characteristics induced by polycyclic aromatic hydrocarbons, different from those in lung cancer attributed to smoking.[6](#tca12987-bib-0006){ref-type="ref"} All of these findings support the hypothesis that patients exposed to coal combustion could display a unique mutational spectrum in lung cancer tumors.[5](#tca12987-bib-0005){ref-type="ref"}, [7](#tca12987-bib-0007){ref-type="ref"}, [63](#tca12987-bib-0063){ref-type="ref"}, [64](#tca12987-bib-0064){ref-type="ref"}

Our study found that FLC and exposure to coal combustion influence clinicopathologic features and gene fusion patterns in NSCLC. Our results reveal the potential uniqueness of the subject population, particularly that inherited susceptibility exerts a greater impact on the age of onset and frequency of gene fusion when subjects are exposed to high levels of carcinogens. Finally, our study showed that dividing a population by genetic, occupational, or environmental factors could partly recreate the diversified distribution picture of gene fusion presented over different reports. Our findings may help to evaluate the effect of FLC and coal exposure on the pathogenesis of lung cancer and highlight the significance of integrating various parameters into clinical and theoretical research.
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